Healthy Participants With Moderate and High Cardiovascular Risk Clinical Trial
Official title:
Aspirin Withdrawal and Clinical Outcome in Patients With Moderate to High Cardiovascular Risk But Without Cardiovascular Disease
While the efficacy of aspirin for the secondary prevention of cardiovascular disease is
evident, the effect of aspirin for primary prevention is unclear. The use of aspirin reduces
cardiovascular mortality and myocardial infarction but increases side effects such as
bleeding. Therefore, the use of aspirin for primary prevention in people without
cardiovascular disease should be determined by individual risk and clinical benefit. The
European guidelines have been changed to not recommend aspirin use in people without
cardiovascular disease, but there are still people taking aspirin for primary prevention. The
purpose of this study is to investigate the effect of aspirin withdrawal on cardiovascular
events in patients without cardiovascular disease.
This is a single center, prospective, randomized clinical study evaluating the safety and
efficacy of withdrawal of aspirin among patients with moderate or high cardiovascular risk.
Patients taking aspirin will be randomly assigned to a group that maintains taking aspirin and a group that discontinues to take aspirin by 1:1 manner. The follow-up duration is five years and clinical outcomes will be investigated. ;